Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
87% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. BIOD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BIOD' s 10-Year Cash to Debt Range
Min: 34.94   Max: No Debt
Current: No Debt

Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
76% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BIOD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -2.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -69.95
BIOD's ROE (%) is ranked lower than
74% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. BIOD: -69.95 )
Ranked among companies with meaningful ROE (%) only.
BIOD' s 10-Year ROE (%) Range
Min: -1034.56   Max: -34.65
Current: -69.95

-1034.56
-34.65
ROA (%) -59.92
BIOD's ROA (%) is ranked lower than
77% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. BIOD: -59.92 )
Ranked among companies with meaningful ROA (%) only.
BIOD' s 10-Year ROA (%) Range
Min: -566.19   Max: -28.58
Current: -59.92

-566.19
-28.58
ROC (Joel Greenblatt) (%) -3559.03
BIOD's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. BIOD: -3559.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2547.75   Max: -884.48
Current: -3559.03

-2547.75
-884.48
EBITDA Growth (3Y)(%) -10.90
BIOD's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. BIOD: -10.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIOD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 51.6
Current: -10.9

0
51.6
EPS Growth (3Y)(%) -21.40
BIOD's EPS Growth (3Y)(%) is ranked lower than
68% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. BIOD: -21.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIOD' s 10-Year EPS Growth (3Y)(%) Range
Min: -44   Max: 113.9
Current: -21.4

-44
113.9
» BIOD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BIOD Guru Trades in Q2 2014

Jim Simons 225,653 sh (+22.04%)
Chuck Royce 20,100 sh (unchged)
» More
Q3 2014

BIOD Guru Trades in Q3 2014

Chuck Royce 20,100 sh (unchged)
Jim Simons 63,300 sh (-71.95%)
» More
Q4 2014

BIOD Guru Trades in Q4 2014

Jim Simons 180,755 sh (+185.55%)
Chuck Royce Sold Out
» More
Q1 2015

BIOD Guru Trades in Q1 2015

Jim Simons 486,884 sh (+169.36%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
BIOD's P/B is ranked higher than
88% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BIOD: 1.70 )
Ranked among companies with meaningful P/B only.
BIOD' s 10-Year P/B Range
Min: 0   Max: 3.3
Current: 1.7

0
3.3
Current Ratio 8.74
BIOD's Current Ratio is ranked higher than
71% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. BIOD: 8.74 )
Ranked among companies with meaningful Current Ratio only.
BIOD' s 10-Year Current Ratio Range
Min: 0.82   Max: 25.41
Current: 8.74

0.82
25.41
Quick Ratio 8.74
BIOD's Quick Ratio is ranked higher than
72% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. BIOD: 8.74 )
Ranked among companies with meaningful Quick Ratio only.
BIOD' s 10-Year Quick Ratio Range
Min: 0.82   Max: 25.41
Current: 8.74

0.82
25.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.80
BIOD's Price/Net Cash is ranked higher than
97% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: 14.50 vs. BIOD: 1.80 )
Ranked among companies with meaningful Price/Net Cash only.
BIOD' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 7.14
Current: 1.8

0.61
7.14
Price/Net Current Asset Value 1.80
BIOD's Price/Net Current Asset Value is ranked higher than
97% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: 10.20 vs. BIOD: 1.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOD' s 10-Year Price/Net Current Asset Value Range
Min: 0.6   Max: 7.1
Current: 1.8

0.6
7.1
Price/Tangible Book 1.70
BIOD's Price/Tangible Book is ranked higher than
94% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. BIOD: 1.70 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOD' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 6.82
Current: 1.7

0.56
6.82
Earnings Yield (Greenblatt) -35.50
BIOD's Earnings Yield (Greenblatt) is ranked lower than
89% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BIOD: -35.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
BIOD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -413.5   Max: 5045.8
Current: -35.5

-413.5
5045.8

Analyst Estimate

Sep15 Sep16 Sep17
EPS($) -0.45 -0.37 -0.53
EPS without NRI($) -0.45 -0.37 -0.53

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BDQN.Germany,
Biodel Inc was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.
» More Articles for BIOD

Headlines

Articles On GuruFocus.com
cooldecency99 note on BIOD May 01 2010 
Biodel Reports Third Quarter Fiscal Year 2009 Financial Results Aug 07 2009 
Biodel to Report Third Quarter Fiscal Year 2009 Results on August 7, 2009 Aug 03 2009 
Biodel Reports First Quarter Fiscal Year 2009 Financial Results and Clinical Update Feb 05 2009 
Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study Jan 30 2009 
Biodel Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results Dec 10 2008 

More From Other Websites
Biodel to Present Data on Concentrated Ultra-Rapid-Acting/Basal Insulin and Glucagon at the 75th... May 28 2015
BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... May 21 2015
Biodel Announces Phase 2b Clinical Trial Initiation of BIOD-531, the Company's Concentrated,... May 21 2015
BIODEL INC Financials May 19 2015
Biodel Appoints Ms. Arlene M. Morris to Its Board of Directors May 18 2015
Coverage initiated on Biodel by ROTH Capital May 18 2015
10-Q for Biodel, Inc. May 09 2015
BIODEL INC Files SEC form 10-Q, Quarterly Report May 07 2015
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2015
Biodel Reports Second Quarter Fiscal Year 2015 Financial Results May 06 2015
Q2 2015 Biodel Inc Earnings Release - 4:00 pm ET May 06 2015
Biodel to Report Second Quarter Fiscal Year 2015 Financial Results on May 6, 2015 May 01 2015
Biodel Announces Pricing of Public Offering of Common Stock May 01 2015
Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior... May 01 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
BIODEL INC Files SEC form 8-K, Other Events Apr 20 2015
BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material... Apr 15 2015
Biodel Announces Pricing of Public Offering of Common Stock Apr 15 2015
BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 06 2015
Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior... Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK